TargetMol

Tegatrabetan

Product Code:
 
TAR-T5642
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5642-1mg1mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-2mg2mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-5mg5mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-1mL1 mL * 10 mM (in DMSO)£141.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-10mg10mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-25mg25mg£247.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-50mg50mg£353.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5642-100mg100mg£548.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BC2059 is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity.
CAS:
1227637-23-1
Formula:
C28H36N4O6S2
Molecular Weight:
588.74
Pathway:
Stem Cells; Cytoskeletal Signaling
Purity:
0.98
SMILES:
C[C@H]1C[C@@H](C)CN(C1)S(=O)(=O)c1ccc2C(=NO)c3ccc(cc3C(=NO)c2c1)S(=O)(=O)N1C[C@@H](C)C[C@@H](C)C1
Target:
Wnt/beta-catenin

References

Fiskus W, Sharma S, Saha S, et al. Pre-clinical efficacy of combined therapy with novel ?-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells[J].Leukemia. 2015 Jun;29(6):1267-78 Savvidou I, Khong T, Cuddihy A, et al. Beta-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma[J]. Molecular Cancer Therapeutics, 2017, 16(9):molcanther.0624.2016. Ueda K, Kumari R, Schwenger E, et al. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer cell. 2021, 39(4): 529-547. e7.